1. Introduction {#s0005}
===============

CML is a hematological malignancy, characterized by the abnormal proliferation of myeloid progenitors of hematopoietic system. It originates from the transformation of a single hematopoietic cell which carries the BCR-ABL translocation that escapes the cell surveillance mechanism. The presence of Bcr-Abl drives the clonal expansion of leukemic progenitor cells which is mainly dependent upon the imbalance between the rate of proliferation and rate of cell death. The cells expressing Bcr-Abl therefore, prolongs the growth factor-independent survival by inhibiting apoptotic machinery ([@bb0005]). Bcr-Abl oncoprotein was found to exert its anti-apoptotic effect both directly and indirectly by deregulating the genes involved in the apoptotic machinery through aberrant expression of anti- and pro-apoptotic genes. This results in the inhibition of release of cytochrome *c* from the mitochondria and subsequent activation of Apaf1 which are found to inhibit the activation of Caspase 9 ([@bb0010]).

Caspase 9 is an initiator caspase which is mainly involved in the intrinsic/mitochondrial mediated apoptotic pathway. Activation of Caspase 9 is often linked to the permeabilization of outer mitochondrial membrane by pro-apoptotic members of BCL2 family. SNPs located either in the promoter region (CASP9-1263A\>G, CASP9 -712C\>T, CASP9 -293 del) or in the exonic region (CASP9 Ex5 +32G\>A) of Caspase 9 are known to modulate the susceptibility to cancer. In silico analysis ([@bb0095]) had revealed creation of additional simian virus-40 protein 1- (Sp1) binding site in presence of CASP9 -1263G allele and elimination of binding sites for Krox-20, NF-1, and ETF transcription factors in the presence of CASP9 -712T allele, while the deletion of 19 (-293\_-275 del CGTGA GGTCAGTGCGGGGA) nucleotides was reported to alter the expression levels of CASP9 gene. CASP9 Ex5 +32G\>A exonic polymorphism results in the substitution of glutamine by arginine at codon 221 (Q221R). This amino acid substitution leads to conformational change in the molecule, which modifies the affinity of Casp9 protein to Apaf-1, thus influencing apoptosis and thereby carcinogenesis ([@bb0035]). Keeping in view the functional significance of the promoter and exonic SNPs of CASP9 gene, the study was planned to assess the role of these SNPs in the development and progression of CML.

2. Materials and methods {#s0010}
========================

2.1. Study design {#s0015}
-----------------

The present case-control study was performed on 999 individuals comprising of 514 controls and 485 CML cases. Age and gender matched control samples without any family history of cancer were obtained from the local population, while the CML cases were recruited from Nizams Institute of Medical Sciences (NIMS), Hyderabad. This study was approved by the Institutional Ethics Committee for Biomedical Research, Osmania University, and ethical committee of the NIMS, Hyderabad. CML patients with primary diagnosis of Ph + ve CML, who are being treated with Imatinib mesylate (IM), irrespective of age group were recruited, while secondary or drug induced CML cases were excluded. The diagnosis of the CML was confirmed based on the complete blood picture (WBC, platelets and % of blasts), cytogenetic tests (to detect the presence of Philadelphia chromosome in blood and bone marrow) and molecular analysis (to detect the levels of BCR-ABL transcript). All the patients who participated in the study were informed about the objectives and a written informed consent was obtained from them. The patient\'s gender, age at the time of diagnosis, occupation and other general information was noted down in prescribed proforma. The clinical information such as- Baseline clinical profile (WBC count, platelet count, % of blast and differential cell count (basophils, eosinophils) and spleen size), Phase of the disease at the time of diagnosis (chronic/accelerated/blast), Hematological response (responders or non-responders), Cytogenetic response (responders or non-responders) and Molecular response (responders or non-responders) was obtained from the tumor registry ([@bb0020]). Three different risk scores were calculated namely Sokal, Hasford and EUTOS scores, using an online calculator [@bb0050]).

IM resistance was categorized either as primary and secondary resistance based on specific criteria as follows. The patients who failed to achieve initial cytogenetic response (at six months) with Imatinib treatment were categorized into primary resistant cases, while patients who initially responded well to IM, but later tend to develop resistance during the course of the treatment were categorized into secondary resistant cases. Any indication of progression or death in chronic phase patients was considered as an event and the Event free survival (EFS) was calculated by taking the time lapsed from the date of diagnosis to the date of either entering into advanced phase (accelerated or blast) or death. All the patients were followed up for a period of five years and the percentage of patients who survived beyond 5 years after diagnosis was calculated and referred as relative five year overall survival (OS).

2.2. Methodology {#s0020}
----------------

Blood samples collected in EDTA were used for genomic DNA isolation by conventional salting out method ([@bb0075]). The purity and concentration of genomic DNA was determined using Nanodrop (TM) 1000 UV/VIS Spectrophotometer (Thermo Fisher Scientific, Waltham, USA). The DNA samples were diluted to 50 ng/μL concentration. PCR was performed independently for four SNPs (CASP9 -1263A\>G, CASP9 -712C\>T, CASP9 -293 del and CASP9 Ex5 +32G\>A) following the PCR conditions which included initial denaturation at 95 °C for 5 min, followed by 35 cycles of denaturation at 94 °C for 1 min, annealing at varied temperature (based on SNP), extension at 72 °C for 1 min and final extension at 72 °C for 7 min using sequence specific primers (BIOSERVE) ([Table 1](#t0005){ref-type="table"}).Table 1PCR conditions used for SNP analysis.Table 1Gene, chromosome location, base change, positionGenotyping methodPrimerAnnealing temperaturePCR ProductCASP9 (1p36.21); -1263A\>G; rs4645978PCR RFLPF:5′-GGGAATACTTTCCTGGCAGG-3′ (sense)\
R:5′-GTCTTCCATTCCCTCTTCCG(C/G)TC-3′ (antisense)59.8 °C234 bpCASP9 (1p36.21); -712C\>T; rs4645981PCR RFLPF:5′-AGTCGCGGAGGTGCCGCCTT-3′ (sense)\
R:5′-AGGGCTAGCCTCGTGCCAG(C/G)C-3′ (antisense)62.5 °C194 bpCASP9 (1p36.21); -293 del; rs4645982PCR assay\
(Hot Start Taq pol)F:5′-CGTTGGAGATGCGTCCTGCG-3′ (sense)\
R:5′-CGCCCTCAGGACGCACCTCT-3′ (antisense)64.5 °C241 bp(++) 222 bp (−−)CASP9 (1p36.21) Ex5 +32G\>A; rs1052576PIRA-PCR: mismatch, sense primer −2 G-to-C5′-GGCTTTGCTGGAGCTGGCCC-3′ (sense)\
5′-AGTACCCAATGCCTGCCCAGGG-3′ (antisense)62.8 °C121 bp

The PCR master-mix was prepared in a 10-μL reaction mix that consisted of 50 ng DNA template, 2.5 mM dNTP mix, 25 pmol of sense and antisense primers, 0.5 U Taq polymerase (Bangalore Genei) and Milli-Q water. PCR products were checked on 3% agarose gel and the products were digested overnight for 16 h and incubated at 37 °C in the water bath using specific restriction digestion enzymes based on SNP ([Table 2](#t0010){ref-type="table"}). Genotyping of the samples was carried out on 4.5% agarose gel and the sizes of the fragments were determined with the help of DNA ladders (50 bp and 100 bp). Some of the samples were randomly genotyped and the results were found to be concordant.Table 2Genotyping of CASP9 polymorphisms after restriction digestion.Table 2Gene & base change, positionGenotyping methodEnzyme (New England Biolabs)Gel band patternCASP9 (1p36.21); -1263A\>G; rs4645978PCR RFLP\
(Taq polymerase)BcoD1\
(37 °C)AA:205 bp,29 bp; AG: 234 bp, 205 bp, 29 bp; GG: 234 bpCASP9 (1p36.21); -712C\>T; rs4645981PCR RFLP\
(Taq polymerase)*Hae*II\
(37 °C)CC:176 bp,18 bp; CT:194 bp,176 bp, 18 bp; TT 194 bpCASP9 (1p36.21); -293 del; rs4645982PCR assay\
(Hot Start Taq polymerase)--+/+:241 bp; −/+:241 bp,222 bp; −/−: 222 bpCASP9 (1p36.21) Ex5 +32 G\>A; rs1052576PIRA-PCR: mismatch, sense primer −2 G-to-C\
(Taq polymerase)*Msp*I (37 °C)GG:102 bp, 19 bp; GA:121 bp, 102 bp, 19 bp; AA: 121 bp

2.3. Statistical analysis {#s0025}
-------------------------

Appropriate statistical analyses were performed to assess the association of CASP9 polymorphisms with CML. An online web tool, SNPSTAT, ([@bb0045]) was used to calculate the genotype frequencies, Hardy Weinberg Equilibrium (HWE) and odds ratios. The allele frequencies and chi-square p-values were calculated using online statistical tools ([@bb0055] and [@bb0060]). The level of significance was taken as p \< 0.05. Haplotype and pairwise linkage disequilibrium analyses were derived using Haploview (version 4.1). SPSS version 22 software was used for analyzing the association of genotype with survival rates (Event free survival and Five year overall survival).

3. Results {#s0030}
==========

3.1. Distribution of epidemiological and clinical variables in CML {#s0035}
------------------------------------------------------------------

In the present study, elevated sex ratio was observed in CML group wherein the frequency of male patients was found to be twice that of females. Major proportion of CML cases was in middle age group (20--40 years) and the overall mean age at onset was found to be 35.86 ± 12.37 years. It was also observed that the higher frequency of CML patients to be agricultural laborers or general laborers and more frequently non-vegetarians. However, area of living (rural or urban) did not show any association with CML ([Table 3](#t0015){ref-type="table"}).Table 3Distribution of epidemiological variables in CML cases and controls.Table 3CharacteristicControls N (%)CML Cases N (%)Mean age at onset ± SDSex ratioGenderMale309 (60.12)312 (64.33)36.03 ± 12.171.80:1Female205 (39.88)173 (35.67)35.55 ± 12.74Age at onset\<20 yrs61 (11.87)36 (7.42)15.08 ± 4.131.4:120--40 yrs278 (54.09)295 (60.82)30.74 ± 5.901.81:1\>40 yrs175 (34.04)154 (31.75)50.53 ± 6.66**1.91:1**Living areaRural280 (57.14)278 (58.77)35.58 ± 11.76**1.96:1**Urban210 (42.86)195 (41.23)35.82 ± 13.151.5:1OccupationAgriculture26 (5.53)94 (19.79)37.88 ± 11.172.48:1Laborers122 (25.96)151 (31.79)35.79 ± 10.85**2.68:1**Others322 (68.51)230 (48.42)34.77 ± 13.641.21:1DietVeg78 (16.15)25 (5.57)42.84 ± 13.841.5:1Non-veg405 (83.85)424 (94.43)35.47 ± 12.31**1.75:1**[^1]

There was a significant elevation in mean levels of WBC, platelet count, Sokal score, Hasford score and EUTOS score with large standard deviation and wide range of values indicating the presence of inter-individual variation. It was observed that 21.49% of CML patients failed to achieve complete cytogenetic response (CCgR). The mean event free survival rate in patients, diagnosed in chronic phase was found to be 69.52 months and relative five year overall survival was found to be 49.51 months ([Table 4](#t0020){ref-type="table"}). Higher frequency of CML patients was observed in high risk group of Sokal (38.43%), intermediate group of Hasford (42.79%) and low risk group of EUTOS (64.19%). Although, the sex ratio was nearly twice in general among all groups, it was found to be more predominant in low and intermediate risk groups of Sokal (1.90:1) and intermediate risk group of Hasford (1.8:1) scoring systems and high risk group (1.78:1) of EUTOS scoring system. Nearly, 90% of patients were diagnosed in the chronic phase as compared to 6.6% and 3.4% of the patients reported in accelerated and blast phase, respectively. With respect to IM response, it was observed that nearly, 74.79% of patients achieved complete hematological response, 63.35% of the patients achieved complete cytogenetic response and 57.89% of the patients achieved complete molecular response ([Table 5](#t0025){ref-type="table"}).Table 4Baseline clinical characteristics of CML patients.Table 4VariableNMean ± SDRangeWBC count461142,368.51 ± 97,451.861100--740,000Platelet count (in lakhs)4573.96 ± 2.430.3--20Sokal score4583.55 ± 45.880.44--982.35Hasford score4581085.76 ± 607.660--5260EUTOS score45874.27 ± 46.050--277% of no CCgr (%)45721.49 ± 8.1611--66Event free survival (months)23969.52 ± 34.701--170Relative overall survival (months)45849.51 ± 18.531--61Table 5Distribution of clinical characteristics of CML patients.Table 5Clinical variablesN (%)Mean age ± SDSex ratioSokal score (458)Low risk134 (29.26%)32.53 ± 11.361.85:1Intermediate risk148 (32.31%)35.66 ± 12.321.90:1High risk176 (38.43%)37.71 ± 12.781.55:1Hasford score (458)Low risk166 (36.24%)34.00 ± 9.671.68:1Intermediate risk196 (42.79%)34.96 ± 13.601.8:1High risk96 (20.96%)39.35 ± 13.28174:1EUTOS score (458)Low risk294 (64.19%)36.16 ± 12.291.70:1High risk164 (35.81%)34.41 ± 12.511.78:1Phase of CML (470)CP423 (90%)35.63 ± 12.341.78:1AP31 (6.60%)36.13 ± 13.012.1:1BC16 (3.40%)31.75 ± 9.331.67:1Hematologic response (365)CHR273 (74.79%)35.47 ± 11.761.76:1PHR56 (15.34%)35.21 ± 10.881.95:1NHR36 (9.86%)35.50 ± 10.662:1Cytogenetic response (352)CCR223 (63.35%)35.17 ± 12.121.65:1PCR63 (17.90%)33.08 ± 10.312.15:1NCR66 (18.75%)35.70 ± 10.801.64:1Molecular response (323)Responders187 (57.89%)35.88 ± 12.031.67:1Non-responders136 (42.11%)34.82 ± 11.941.57:1

3.2. Genotype distribution of CASP9 polymorphisms in CML {#s0040}
--------------------------------------------------------

HapMap was constructed in order to compare the distribution of the allele frequencies of different SNPs of CASP9 under study with those reported from different populations like South Asian (SAS), East Asian (EAS), Asian (HCB), Asian (CHB), Asian (JPT), Ad Mixed American (AMR), European (EUR), European (CEU), African (AFR) and Sub-Saharan African (YRI). It was observed that the distribution of the variant allele frequencies of CASP9 -1263A\>G and CASP9 -293 del polymorphisms were comparable to South Asian (SAS) population and Ad Mixed American (AMR) and European (EUR- 0.49) populations, respectively while variant allele frequency of CASP9 -712C\>T polymorphism was greater than Ad Mixed American (AMR), African (AFR) and European (EUR) populations whereas CASP9 Ex5 +32G\>A was greater than that of other populations like European (CEU), Asian (HCB), Asian (CHB), Asian (JPT) and Sub-Saharan African (YRI) ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Hapmap data of Caspase 9 polymorphisms.Fig. 1

[Table 6](#t0030){ref-type="table"} shows the distribution of genotype and allele frequencies of CASP9 -1263A\>G, CASP9 -712C\>T, CASP9 -293 del and CASP9 Ex5 +32G\>A polymorphisms among controls and cases. The allele distribution of CASP9 -712C\>T and CASP9 -293 del polymorphisms had shown significant deviation from HWE whereas CASP9 Ex5 +32G\>A polymorphism was in HWE in both controls and cases, while CASP9 -1263A\>G polymorphism had shown significant deviation from HWE in controls but not in cases. The possible reason for deviation from HWE could be due to selective forces acting against or in favor of either of these alleles or due to elevated frequency of heterozygotes compared to both homozygotes ([Table 6](#t0030){ref-type="table"}). It was observed that presence of either CASP9 -1263AG or CASP9 -1263GG genotypes was significantly associated with increased risk to develop CML under co-dominant, dominant and recessive models, respectively, with corresponding increase in the frequency of G allele. Conversely, the CASP9 -712CT genotype/T allele of CASP9 -712C\>T polymorphism significantly conferred reduced risk for the development of CML under codominant, dominant and over-dominant models. With respect to CASP9 -293 del polymorphism, the frequency of heterozygous (+/−) genotype was elevated among controls as compared to cases and was associated with reduced risk for CML development under co-dominant, dominant and over-dominant models. However, the allele frequency distribution of CASP9 -293 del polymorphism did not reveal any significant difference between cases and controls. The present study, however, failed to reveal significant association of CASP9 Ex5 +32G\>A polymorphism with CML development ([Table 6](#t0030){ref-type="table"}).Table 6Distribution of CASP9 -1263 A\>G polymorphisms among CML cases and controls.Table 6ModelGenotypeControlCaseOR (95% CI)p-Value*CASP9 -1263A\>G (Hardy Weinberg Equilibrium: controls p = 0.00028; cases p = 0.78)*CodominantAA151 (29.61%)79 (16.4%)1.00**\<0.0001\***AG214 (41.96%)229 (47.4%)**2.03 (1.46--2.83)**GG145 (28.43%)175 (36.2%)**2.28 (1.61--3.24)**DominantAA151 (29.61%)79 (16.4%)1.00**\<0.0001\***AG + GG359 (70.4%)404 (83.6%)**2.13 (1.57--2.90)**RecessiveAA+AG365 (71.6%)308 (63.8%)1.00**0.01\***GG145 (28.43%)175 (36.2%)**1.42 (1.08--1.86)**OverdominantAA+GG296 (58%)254 (52.6%)1.00**0.08**^**\#**^AG214 (42%)229 (47.4%)**1.25 (0.97--1.61)**Wild alleleA516 (50.59%)387 (40.06%)1.00Variant alleleG504 (49.41%)579 (59.94%)**1.54 (1.29--1.84)\<0.0001\***  *CASP9 -712C\>T (Hardy Weinberg Equilibrium: controls p ≤0.0001; cases p ≤0.0001)*CodominantCC407 (80.12%)432 (89.6%)1.00**1e−04\***CT69 (13.58%)27 (5.6%)**0.38 (0.24--0.60)**TT32 (6.30%)23 (4.8%)0.67 (0.38--1.16)DominantCC407 (80.1%)432 (89.6%)1.00**\<0.0001\***CT+TT101 (19.9%)50 (10.4%)**0.47 (0.33--0.68)**RecessiveCC+CT476 (93.7%)459 (95.2%)1.00**0.26**TT32 (6.30%)23 (4.8%)0.73 (0.42--1.27)OverdominantCC+TT439 (86.4%)455 (94.4%)1.00**\<0.0001\***CT69 (13.6%)27 (5.6%)**0.39 (0.24--0.62)**Wild alleleC883 (86.91%)891 (92.43%)1.00Variant alleleT133 (13.09%)73 (7.57%)**0.55 (0.40--0.74)0.0001\***  *CASP9 -293 DEL (Hardy Weinberg Equilibrium: controls p = 0.061; cases p ≤0.0001)*Codominant+/+121 (23.87%)140 (29.3%)1.00**0.03\***+/−231 (45.56%)180 (37.7%)**0.67 (0.49--0.92)**−/−155 (30.57%)158 (33%)0.88 (0.63--1.22)Dominant+/+121 (23.87%)140 (29.3%)1.00**0.05\***(+/−) + (−/−)386 (76.1%)338 (70.7%)**0.75 (0.57--1.00)**Recessive(+/+) + (+/−)352 (69.4%)320 (67%)1.000.41−/−155 (30.6%)158 (33%)1.12 (0.86--1.47)Overdominant(+/+) + (−/−)276 (54.4%)298 (62.3%)1.00**0.01\***+/−231 (45.6%)180 (37.7%)**0.72 (0.56--0.93)\***Wild allele+473 (46.65%)460 (48.12%)1.00Variant allele−541 (53.35%)496 (51.88%)0.94 (0.79--1.13)0.52  *CASP9 Ex5 +32G\>A (Hardy Weinberg Equilibrium: controls p = 0.24; cases p = 0.26)*CodominantGG83 (16.40%)78 (16.5%)1.001GA261 (51.58%)244 (51.5%)0.99 (0.70--1.42)AA162 (32.12%)152 (32.1%)1.00 (0.68--1.46)DominantGG83 (16.4%)78 (16.5%)1.000.98GA+AA423 (83.6%)396 (83.5%)1.00 (0.71--1.40)RecessiveGG+GA344 (68%)322 (67.9%)1.000.99AA162 (32%)152 (32.1%)1.00 (0.77--1.31)OverdominantGG+AA245 (48.4%)230 (48.5%)1.000.98GA261 (51.6%)244 (51.5%)1.00 (0.77--1.28)Wild AlleleG427 (42.19%)400 (42.19%)1.00Variant AlleleA585 (57.81%)548 (57.81%)1.00 (0.84--1.20)0.99[^2]

3.3. Association of CASP9 polymorphisms with phase of CML {#s0045}
---------------------------------------------------------

When the data was compared with respect to the phase of the CML at the time of diagnosis, it was observed that the frequencies of AG and GG genotypes of CASP9 -1263 A\>G polymorphism, in general, were significantly elevated in CML patients irrespective of phase at the time of diagnosis and significant odds ratios were obtained for chronic phase CML patients carrying either AG (OR-1.99, 95% CI-1.41--2.80) or GG (OR-2.20, 95% CI-1.53--3.16) genotypes. When the data on chronic phase CML was further stratified based on their progression as observed during follow up, it was noted that risk conferred by AG or GG was more pronounced for those who progressed into advanced phase (AG- OR- 2.43, 95% CI- 1.4--3.97; GG- OR- 2.46, 95% CI-1.46--4.14) as compared to patients who did not progress (AG- OR- 1.75, 95% CI - 1.17--2.61; GG- OR- 2.06, 95% CI-1.35--3.14) suggesting the role of this polymorphism in progression of CML. In case of CASP9 -712C\>T polymorphism, it was observed that the frequencies of CT and TT genotypes were reduced in patients diagnosed in chronic phase as compared to controls, while the frequency of TT genotype was elevated in patients with accelerated phase. However, small sample size in these groups (accelerated and blast phase) does not permit to draw inference. The genotype distribution with respect to CASP9 -293 del and CASP9 Ex5 +32G\>A polymorphisms did not reveal significant association ([Table 7](#t0035){ref-type="table"}).Table 7Genotype distribution of CASP9 polymorphisms with respect to phase of CML.Table 7CASP9 -1263A\>GAAAGOR (95% CI)GGOR (95% CI)p-ValueControls151 (29.61)214 (41.96)1.00145 (28.43)1.00**0.00008\***At the time of diagnosisChronic71 (16.9)200 (47.5)**1.99 (1.41--2.80)**150 (35.6)**2.20 (1.53--3.16)**Accelerated4 (12.9)16 (51.6)2.82 (0.93--8.60)11 (35.5)2.86 (0.89--9.20)Blast1 (6.2)9 (56.2)6.35 (0.0--50.6)6 (37.5)6.25 (0.74--52.54)Progressed (chronic phase)Without progression46 (18.33)114 (45.42)**1.75 (1.17--2.61)**91 (36.25)**2.06 (1.35--3.14)**With progression25 (14.71)86 (50.59)**2.43 (1.4--3.97)**59 (34.71)**2.46 (1.46--4.14)**  CASP9 -712C\>TCCCTOR (95% CI)TTOR (95% CI)p-ValueControls407 (80.12)69 (13.58)1.0032 (6.30)1.00**0.000006\***\
\
**0.00007\***\
**(Yates)**At the time of diagnosisChronic382 (90.7)24 (5.7)**0.37 (0.22--0.60)**15 (3.6)**0.50 (0.27--0.94)**Accelerated24 (80)1 (3.3)0.25 (0.03--1.85)5 (16.7)2.65 (0.95--7.41)Blast13 (81.2)2 (12.5)0.90 (0.20--4.10)1 (6.2)0.9 (0.12--7.71)Progressed (chronic phase)Without progression229 (91.24)13 (5.18)**0.33 (0.18--0.62)**9 (3.59)0.50 (0.23--1.07)With progression153 (90.00)11 (6.47)**0.42 (0.22--0.82)**6 (3.53)0.50 (0.20--1.21)  CASP9 -293 del+/++/−OR (95% CI)−/−OR (95% CI)p-ValueControls121 (23.87)231 (45.56)1.00155 (30.57)1.000.40At the time of diagnosisChronic120 (28.7)164 (39.2)0.72 (0.51--0.9)134 (32.1)0.87 (0.62--1.23)Accelerated10 (34.5)10 (34.5)0.52 (0.21--1.29)9 (31)0.70(0.22--1.78)Blast5 (31.2)4 (25)0.42 (0.11--1.59)7 (43.8)1.09(0.33--3.52)Progressed (chronic phase)Without progression77 (30.92)94 (37.75)0.64 (0.44--0.92)78 (31.33)0.79(0.53--1.17)With progression43 (25.44)70 (41.42)0.5 (0.55--1.33)56 (33.14)1.01 (0.64--1.61)  CASP9 Ex5 +32G\>AGGGAOR (95% CI)AAOR (95% CI)p-ValueControls83(16.40)261(51.58)1.00162(32.02)1.000.89At the time of diagnosisChronic67 (16.2)218 (52.7)1.03 (0.71--1.49)129 (31.2)0.98 (0.66--1.46)Accelerated6 (20)15 (50)0.80 (0.30--2.11)9 (30)0.77 (0.26--2.23)Blast0 (0)9 (56.2)6.07 (0.35--105.3)7 (43.8)7.71 (0.43--136.6)Progressed (chronic phase)Without progression44 (17.67)127 (51.00)0.92 (0.60--1.40)78 (31.33)0.91 (0.58--1.43)With progression23 (13.94)91 (55.15)1.26(0.75--2.11)51 (30.91)1.13 (0.65--1.99)[^3]

3.4. Association of CASP9 polymorphisms with respect to IM resistance (primary and secondary) {#s0050}
---------------------------------------------------------------------------------------------

The genotype data of chronic phase patients was further analyzed with respect to primary or secondary resistance. It was observed that the CASP9 -1263AG and CASP9 -1263GG genotypes had significantly increased the risk by several folds for both primary and secondary resistance, while the distribution of CASP9 -712C\>T and CASP9 -293 del polymorphisms did not reveal any significant association. However, the AA genotype of CASP9 Ex5 +32G\>A polymorphism was significantly associated with increased risk for secondary resistance (AA- OR-3.54, 95% CI- 1.02--12.22) ([Table 8](#t0040){ref-type="table"}).Table 8Genotype distribution of CASP9 polymorphisms among primary and secondary resistant CML cases and controls.Table 8CASP9 -1263A\>GAAAGOR (95% CI)GGOR (95% CI)p-ValueControls151(29.61)214(41.96)1.00145(28.43)1.00**0.003\***Primary resistant cases6 (11.76)28 (54.90)**3.29 (1.33--8.15)**17 (33.33)**3.01 (1.15--7.89)**Secondary resistant cases4 (9.76)18 (43.90)**3.18 (1.05--9.58)**19 (46.34)**4.82 (1.59--14.60)**  CASP9 -712C\>TCCCTOR (95 CI)TTOR (95 CI)p-ValueControls407 (80.12)69 (13.58)1.0032 (6.30)1.000.36\
0.58 (yates)Primary resistant cases44 (86.3)4 (7.8)0.54 (0.19--1.58)3 (5.9)0.87 (0.26--2.95)Secondary resistant cases36 (85.71)2 (4.76)0.31 (0.07--1.31)4 (9.52)1.39 (0.46--4.15)  CASP9 -293 del+/++/−OR (95 CI)−/−OR (95 CI)p-ValueControls121 (23.87)231 (45.56)1.00155 (30.57)1.000.45Primary resistant cases10 (20.00)23 (46.00)1.20 (0.55--2.60)17 (34.00)1.33 (0.59--3.01)Secondary resistant cases9 (21.95)14 (34.15)0.82 (0.34--1.95)18 (43.90)1.54 (0.67--3.56)  CASP9 Ex5 +32G\>AGGGAOR (95 CI)AAOR (95 CI)p-ValueControls83 (16.40)261 (51.58)1.00162 (32.02)1.000.13Primary resistant cases7 (14.58)26 (54.17)1.18 (0.49--2.81)15 (31.25)1.10 (0.43--2.81)Secondary resistant cases3 (7.32)17 (41.46)1.81 (0.52--6.33)21 (51.22)**3.54 (1.02--12.22)**[^4]

3.5. Association of CASP9 polymorphisms with the survival rate (event free and five overall survival rate) {#s0055}
----------------------------------------------------------------------------------------------------------

Kaplan Meier analysis of both event free and five year overall survival rates had failed to reveal significant association of CASP9 -1263G\>A, CASP9 -712C\>T, CASP9 -293 del and CASP9 Ex5 +32 G\>A polymorphisms with CML ([Table 9](#t0045){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}, [Table 10](#t0050){ref-type="table"} and [Fig. 3](#f0015){ref-type="fig"}).Table 9Kaplan Meier Survival analysis for event free survival (EFS) rate with respect to CASP9 polymorphisms.Table 9Sl noCASP9Chronic phase (%)(EFS in months) mean ± SEMMedianp-Value*CASP9 -1263 A\>G*1AA25 (14.71)33.20 ± 4.9534.000.17^a^2AG86 (50.59)33.97 ± 2.9629.003GG59 (34.70)43.83 ± 3.9341.00Total**17037.28 ± 2.1732.00**  *CASP9 -712 C\>T*1CC153 (90.00)36.99 ± 2.2833.000.86^a^2CT11 (6.47)36.64 ± 9.7823.003TT6 (3.53)45.83 ± 10.6231.00Total**17037.28 ± 2.1732.00**  *CASP9 -293 DEL*1+/+43 (25.44)41.40 ± 4.0235.000.67^a^2+/−70 (41.42)35.73 ± 3.8728.003−/−56 (33.14)36.50 ± 3.2637.00Total**16937.43 ± 2.1833.00**  *CASP9 Ex5 +32G\>A*1GG23 (13.94)32.74 ± 5.4831.0000.08^a^2GA91 (55.15)34.10 ± 2.8029.0003AA51 (30.91)46.06 ± 4.3541.000Total**16537.61 ± 2.2133.000**[^5]Fig. 2Kaplan Meier Survival curves for event free survival (EFS) rate with respect to Caspase 9 polymorphisms.Fig. 2Table 10Kaplan Meier Survival analysis for five year overall survival (OS) rate with respect to CASP9 polymorphisms.Table 10Sl noN (%)Chronic phase (%)(OS in months) mean ± SEMMedianp-Value*CASP9 -1263A\>G*1AA74 (16.41)69 (93.24)49.78 ± 2.0761.0000.19^a^2AG221 (49.00)197 (89.14)51.88 ± 1.1661.0003GG156 (34.59)143 (91.67)53.48 ± 1.2061.000Total**451409 (90.69)52.09** **±** **0.7861.000**  *CASP9 -712 C\>T*1CC403 (89.56)371 (92.06)51.93 ± 0.8361.0000.37^a^2CT27 (6.00)24 (88.89)50.56 ± 3.4761.0003TT20 (4.44)14 (70.00)55.42 ± 2.9661.000Total**450409 (90.89)52.00** **±** **0.7861.000**  *CASP9 -293 del*1+/+128 (28.70)115 (89.84)50.00 ± 1.6161.000.18^a^2+/−172 (38.57)159 (92.44)53.84 ± 1.1561.003−/−146 (32.73)132 (90.41)51.37 ± 1.4261.00**Total446406 (91.03)51.95** **±** **0.7961.00**  *CASP9 Ex5 +32G\>A*1GG71 (16.03)65 (91.55)50.57 ± 2.1961.0000.25^a^2GA234 (52.82)211 (90.17)52.48 ± 1.0561.0003AA138 (31.15)126 (91.30)52.60 ± 1.3361.000Total**443402 (90.74)52.33 ± 0.7861.000**[^6]Fig. 3Kaplan Meier Survival Curves for five year overall survival (OS) rate with respect to Caspase 9 polymorphisms.Fig. 3

3.6. Haplotype analysis of CASP9 polymorphisms {#s0060}
----------------------------------------------

The haplotype analysis of all four CASP9 SNPs including 3 promoter SNPs and one exonic SNP (CASP9 -1263 A\>G, CASP9 -712 C\>T, CASP9 -293 del and CASP9 Ex5 +32G\>A) was carried out to find out the risk haplotypes for CML development. Out of 10 haplotypes obtained, it was observed that two haplotypes G-C-del (+)-G (OR-1.61, 95% CI-0.97--2.65, p- 0.06^\#^) and G-C-del(−)-G (OR-2.09, 95% CI-0.94--4.66, p- 0.07^\#^) haplotypes were found to be associated with increased risk for the development of CML, while A-C-del (−)-A (OR-0.33, 95% CI- 0.20--0.55, p - \<0.0001\*) and A-T-del (+)-G (OR-0.32 (0.15--0.69), p- 0.004\*) were significantly associated with decreased risk for the development of CML ([Table 11](#t0055){ref-type="table"}).Table 11Haplotype analysis of promoter polymorphisms (CASP9 -1263 A\>G, CASP9 -712 C\>T, CASP9 -293 del) and exonic (CASP9 EX+5 32G\>A) among cases and controls.Table 11SL no.CASP9 -1263 A\>GCASP9 -712 C\>TCASP9 -293 delCASP9 1207 G\>AFrequencyOR (95% CI)p-ValueTotalControlsCases1GC−A0.36290.33960.38761.00−2AC+G0.2980.30710.29010.87 (0.69--1.10)0.253GC+A0.05830.04560.07151.23 (0.86--1.76)0.264AC−A0.05620.08320.0279**0.33 (0.20--0.55)\<0.0001\***5GT−A0.04840.05830.03990.72 (0.47--1.11)0.146GC+G0.04290.03090.0543**1.61 (0.97--2.65)0.06**^**\#**^7AC+A0.03440.02960.0391.08 (0.65--1.78)0.788AT+G0.0270.04150.0117**0.32 (0.15--0.69)0.004\***9AC−G0.0260.02320.0291.01 (0.55--1.87)0.9710GC−G0.01740.33960.0248**2.09 (0.94--4.66)0.07**^**\#**^[^7]

3.7. Linkage disequilibrium analysis of CASP9 polymorphisms {#s0065}
-----------------------------------------------------------

In the present study, pairwise LD analysis was performed for 4 SNPs independently in both cases and controls. It was observed that the all the four SNPs of CASP9 gene were found to be associated with either high or moderate LD in both cases and controls. CASP9 Ex5 +32 G\>A and CASP9 -1263A\>G exhibited high LD in both controls (D′-0.769) and cases (D′-0.702) while the SNP combinations of CASP9 Ex5 +32 G\>A and CASP9 -293 del showed strong LD in controls (D′- 0.824) but moderate LD in cases (0.714). Further, comparison of LD values of CASP9 -293 del and CASP9 -1263A\>G had shown moderate LD in controls (0.633) while high LD in cases (0.707). However, in case of CASP9 -1263A\>G and CASP9 -712C\>T SNPs, a moderate LD was presented in cases (0.547) while was absent in controls (0.051) ([Table 12](#t0060){ref-type="table"}, [Table 13](#t0065){ref-type="table"} and [Fig. 4](#f0020){ref-type="fig"}).Table 12Pairwise LD for Caspase 9 polymorphisms studied in cases.Table 12[^8][^9]Table 13Pairwise LD for Caspase 9 polymorphisms studied in controls.Table 13[^10][^11]Fig. 4LD plot of Caspase 9 SNPs in controls and cases.Fig. 4

4. Discussion {#s0070}
=============

Caspase 9 is the initiator caspase involved in mitochondrial-mediated/intrinsic apoptotic pathway. It is encoded by CASP9 gene which is located on chromosome 1 at p36.21 position ([@bb0030]). Human CASP9 gene consists of 9 exons and 8 introns and spans over 35 kb region. Caspase 9 plays an important role in apoptosis and is thought to act as tumor suppressor gene. Initially, Caspase 9 exists as inactive proenzyme which undergoes proteolytic cleavage at conserved aspartic residues (Asp315 and Asp330) to produce large and small sub-units which further dimerize into active form. Although, several SNPs have been reported, four SNPs namely CASP9-1263G\>A, CASP9 -712 C\>T, CASP9 -293 del (−293 to -275 del CGTGAGGTCAGTGCGGGG A)) and CASP9 Ex5 +32G\>A are of particular interest as the presence of these SNPs in the promoter and exonic region are known to influence the expression of the gene. Hence, in the present study, the association of these SNPs (promoter and exonic) with the development and progression of CML was analyzed.

The results of the present study with respect to CASP9 -1263G\>A polymorphism had revealed that CASP9 -1263AG/GG genotypes and G allele might confer risk for the development of CML which was in accordance with case-control studies on breast cancer by [@bb0105] who reported individuals with CASP9 -1263AG or CASP9 -1263GG genotypes were at higher risk for breast cancer. Studies on other cancers like pancreatic cancer and papillary thyroid carcinoma also revealed the increased risk associated with the G allele ([@bb0100]; [@bb0110]). However, contrary results were obtained from the studies on other cancers like lung ([@bb0095]), bladder ([@bb0025]), prostate ([@bb0070]) and gastric cancer ([@bb0090]) as well as meta-analysis of 9 different studies (prostate) which revealed reduced risk associated with G allele to develop cancer in Asian population ([@bb0115]). The increased frequency of AG and GG genotypes irrespective of phase of CML and elevated frequency of AG genotype in chronic CML patients with subsequent progression indicated possible role of SNP in CML development and progression. Significant association of GG genotype with both primary and secondary resistance further confirmed the importance of this SNP in determining Imatinib response.

The results with respect to CASP9 -712C\>T polymorphism suggested that the presence of CASP9 -712T allele was associated with the reduced risk for the development of CML. Previous studies on transcription factor binding sites using Alibaba2 programme had revealed the loss of binding sites for Krox-20, NF-1, and ETF transcription factors in the presence of -712 T allele resulting in reduced promoter activity and decreased apoptosis ([@bb0095]). The results of the present study were in disagreement with the earlier reports on lung cancer ([@bb0095]; [@bb0085]), breast cancer ([@bb0105]), Non-Small Cell Lung Cancer ([@bb0065]) and AML ([@bb0015]) where the T allele was found to be significantly associated with increased risk which was also supported by meta-analysis studies, where the population based stratification of the data revealed significant risk associated with T allele to develop lung cancer ([@bb0115]). It may be possible that T allele as such may not offer protection against CML in view of the reduced apoptosis associated with the allele, but may appear to do so by being in equilibrium with other promoter SNPs favoring apoptosis.

Presence of heterozygote CASP9 -293 del (+/−) genotype may confer protection against CML as confirmed by the present case-control study. The results obtained in the present study were in agreement with the study by [@bb0025], who reported protective effect exerted by heterozygous (−/+) genotype in high-risk non-muscle-invasive bladder cancer (NMIBC). However, studies on lung ([@bb0095]), prostate cancer ([@bb0070]) and AML ([@bb0015]) failed to reveal association of CASP9 -293 del polymorphism with cancer risk. CASP9 -293 del (+/−) genotype conferred protection against CML risk as evidenced from observation made with respect to phase of the disease and IM response, while the homozygous CASP9 -293 del (−/−) genotype conferred increased risk for the progression as observed by the elevated frequency of CASP9 -293 del (−/−) genotype in patients diagnosed in blast crisis and in secondary resistance cases. These results therefore indicated that the presence of a single dose of a normal CASP9 -293 del (+) allele in heterozygotes might be able to compensate the risk conferred by deletion allele, whereas deletion of 19 nucleotides in the promoter region, on both chromosomes (−/−) might affect the activity of CASP9, there by apoptosis.

In CASP9 Ex5 +32G\>A polymorphism, the transition of G allele with A leads to a conformational change in the structure of Caspase 9 which in turn could modify the affinity of Caspase 9 protein to Apaf-1, thereby affecting the apoptotic machinery. Although several studies have reported the association of CASP9 Ex5 +32G\>A polymorphism with cancer susceptibility, the results of present study however, failed to reveal significant association of this polymorphism with the development and progression CML. The results of the present study were in agreement with earlier studies on lung cancer ([@bb0120]) and AML ([@bb0015]). However, contradictory results were reported in the studies carried out on women with non-Hodgkin lymphoma ([@bb0080]) and multiple myeloma ([@bb0040]) where the variant 'A' allele was found to be associated with decreased risk. The decreased risk associated with A allele was further supported by two independent meta-analysis studies carried out on several cancers ([@bb0115]; [@bb0125]). Although significant association of CASP9 Ex5 +32G\>A polymorphism was not observed with the development of CML in the present study, it was observed that the CASP9 Ex5 +32AA genotype had increased the risk to develop secondary resistance which indicated the possibility of interaction between variant genotype and other Bcr/Abl dependent or independent mechanisms.

There was no significant association of CASP9 polymorphisms with mean EFS and relative five year overall survival rates. Haplotype analysis performed to find out the association of CASP9 -1263 A\>G, CASP9 -712 C\>T, CASP9 -293 del and CASP9 Ex5 +32G\>A with the development of CML had confirmed that the presence of variant G allele of CASP9 -1263 A\>G might be independently conferring risk for the development of CML. The presence of strong LD observed between SNPs of CASP9 genes indicated that these promoter SNPs tend to move together because of their close physical vicinity. However, the presence of LD in cases and absence in controls as observed in the case of SNP combination of CASP9 -1263A\>G and CASP9 -712C\>T might be because of the hitchhiking effect, a phenomenon where an allele changes its frequency not because of its natural selection, but, because of its presence near another SNP, which is undergoing a selective sweep.

5. Conclusion {#s0075}
=============

The results of the present study concludes that the G allele of CASP9 -1263A\>G polymorphism might confer risk for the development and progression of CML while CASP9 -712C\>T and CASP9 -293 del SNPs might confer protection against development of CML. The presence of CASP9 -293 del (−/−) and CASP9 Ex5 +32 AA genotypes might confer risk for the progression.
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[^1]: CML cases: Mean age = 35.86 ± 12.37; SEM = 0.56; median = 35 (4--80).

[^2]: OR- odds ratio adjusted by age and sex; p value- χ^2^ p value; \*p \< 0.05; ^\#^p \< 0.10.

[^3]: OR- odds ratio adjusted by age and sex; p value- χ^2^ p value; \*p \< 0.05; ^\#^p \< 0.10.

[^4]: OR- odds ratio adjusted by age and sex; p value- χ^2^ p value; \*p \< 0.05; ^\#^p \< 0.10.

[^5]: a\) Log Rank (Mantle Cox) p value; p value- χ^2^ p value; \*p \< 0.05; ^\#^p \< 0.10.

[^6]: a\) Log Rank (Mantle Cox) p value; p value- χ^2^ p value; \*p \< 0.05; ^\#^p \< 0.10.

[^7]: Global haplotype association p-value: \<0.0001; OR- odds ratio adjusted by age and sex; p value- χ^2^ p value; \*p \< 0.05; ^\#^p \< 0.10.

[^8]: Strength of LD between any two markers is represented by the intensity of color box.

[^9]: Red color: Higher probability(closer to 1); White: Probability Approaches random (0.5); Blue: Slightly higher than random; Light red: Between red and blue.

[^10]: Strength of LD between any two markers is represented by the intensity of color box.

[^11]: Red color: Higher probability(closer to 1); White: Probability Approaches random (0.5); Blue: Slightly higher than random; Light red: Between red and blue.
